Financial Performance - For the fiscal year ending December 31, 2025, total revenue was HKD 139,112,000, a decrease of 25% from HKD 185,357,000 in the previous year[3] - Gross profit for the fiscal year was HKD 50,644,000, down 38% from HKD 81,858,000 in the prior year[3] - The net loss for the year was HKD 46,848,000, compared to a net loss of HKD 50,600,000 in the previous year, indicating a slight improvement[3] - Total customer contract revenue decreased to HKD 139,112,000 in 2025 from HKD 185,357,000 in 2024, a decline of about 25%[28] - The group reported a net loss attributable to equity holders of HKD 46,678,000 in 2025, compared to a loss of HKD 46,355,000 in 2024, indicating a slight increase in losses[40] - The net loss attributable to equity holders for the year was approximately HKD 46,700,000, compared to a loss of HKD 46,400,000 in 2024[61] Revenue Breakdown - For the fiscal year ending December 31, 2024, the revenue generated from external customers in the dental business was HKD 178,981,000, while the health business generated HKD 6,376,000, totaling HKD 185,357,000[19] - For the fiscal year ending December 31, 2025, the revenue from external customers in the dental business decreased to HKD 132,034,000, and the health business increased to HKD 7,078,000, totaling HKD 139,112,000[20] - Revenue from the dental business, which includes the manufacturing and sale of dentures and dental tools, fell to HKD 132,034,000 in 2025 from HKD 178,981,000 in 2024, a decrease of approximately 26%[28] - The company's dental business generated revenue of approximately HKD 132,000,000, a decrease of about HKD 47,000,000 from HKD 179,000,000 in 2024, attributed to price reductions from government procurement policies[63] Expenses and Costs - Research and development expenses increased to HKD 16,911,000 from HKD 12,477,000, reflecting a 35% rise year-over-year[3] - Employee costs, including directors' remuneration, totaled HKD 103,570,000 in 2025, down from HKD 113,789,000 in 2024, reflecting a reduction of approximately 9%[33] - Sales and distribution costs increased by 7.6% to approximately HKD 51,200,000, primarily due to higher marketing and promotional expenses[69] - Administrative expenses decreased by approximately HKD 10,900,000 or 23.7% from HKD 46,000,000 in FY2024 to HKD 35,100,000 in FY2025, primarily due to lower labor costs and improved management efficiency[70] - Other income, net of losses, decreased significantly to HKD 1,583,000 in 2025 from HKD 5,162,000 in 2024, a drop of about 69%[32] Assets and Liabilities - Total assets decreased to HKD 657,709,000 from HKD 717,593,000, a decline of approximately 8%[5] - Current liabilities decreased to HKD 64,602,000 from HKD 84,028,000, a reduction of about 23%[5] - The company's equity attributable to shareholders decreased to HKD 403,375,000 from HKD 431,153,000, a decline of approximately 6%[6] - The total liabilities as of December 31, 2024, were HKD 91,102,000, while total liabilities as of December 31, 2025, decreased to HKD 73,212,000[22] - Trade receivables decreased to HKD 76,360,000 in 2025 from HKD 111,201,000 in 2024, a decline of 31.3%[50] Investments and Acquisitions - The investment in Zhuhai Partnership, representing a 5.51% equity stake, was acquired for RMB 180,000,000, equivalent to HKD 220,410,000[42] - The company has agreed to acquire Chongxing Limited for approximately HKD 24,412,214, with the transaction contingent upon certain conditions[58] - The group has not engaged in any purchases, sales, or redemptions of its listed securities during the year[93] Future Plans and Market Outlook - The group aims to become a leader in high-end dental consumables and regional sports rehabilitation in China, focusing on core brands "Meijia" and "Bijijia" as development engines[86] - The Chinese dental market is expected to maintain rapid growth, with significant potential for development, driven by rising consumer spending and increased oral health awareness[87] - The group plans to expand its sales network both domestically and internationally (e.g., in the U.S.) and enhance production capacity in China, targeting high-end dental products with cosmetic functions[87] - The rehabilitation business is projected to benefit from policy support, with a focus on brand building and local market penetration to enhance regional influence by 2026[89] Corporate Governance - The board of directors includes both executive and independent non-executive members[99] - The announcement is made by the chairman and executive director, Guo Yingcheng[99] - The audit committee has reviewed the group's financial performance and internal controls, ensuring compliance with accounting standards and regulations[97] Shareholder Communication - The annual performance announcement is published on the company's website and the Hong Kong Stock Exchange website[99] - The 2025 annual report will be sent to shareholders and published according to listing rules at an appropriate time[99] - A share consolidation proposal has been announced, merging every 50 existing shares into 1 new share with a par value of HKD 0.0625[90]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司證券之邀請或要約。 Kaisa Health Group Holdings Limited 876 (1)涉及根據特定授權發行代價股份之 非常重大收購及關連交易； (2)委任獨立財務顧問； (3)建議股份合併；及 (4)建議更改每手買賣單位 獨立董事委員會及獨立股東之獨立財務顧問 本公司之財務顧問 收購事項 於二零二六年三月十八日，本公司（作為買方）與賣方（作為賣方）訂立該協議， 據此本公司有條件同意購買，而賣方有條件同意出售銷售股份（即目標公司的 全部已發行股本），代價為人民幣21,603,729元（相等於約24,412,214港元），並將 由以下方式全數償付： 1 假設股份合併已生效，該2,789,967股代價股份佔：(i)於本公告日期本公司現有 已發行股本約2.77%；及(ii)經配發及發行代價股份擴大後本公司已發行股本約 2.69%（在各情況下均已計及 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Kaisa Health Group Holdings Limited 876 董事會會議通告 主席兼執行董事 佳兆業健康集團控股有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司將 於二零二六年三月二十五日（星期三）舉行董事會會議，藉以（其中包括）考慮及批 准本公司及其附屬公司截至二零二五年十二月三十一日止年度之年度業績及其發 佈，以及考慮派發末期股息之建議（如適用）。 承董事會命 佳兆業健康集團控股有限公司 郭英成 香港，二零二六年三月十三日 於本公告日期，本公司執行董事為郭英成先生、羅軍先生、 羅婷婷女士、劉立好先生、謝斌鴻先生及葉豪達先生；及本公司獨立非執行董事 為劉彥文博士、呂愛平博士及李祉瑩女士。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 佳兆業健康集團控股有限公司 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 1. 股份分類 普通股 股份類別 不適用 於香港聯交所上市 (註1) 是 證券代號 (如上市) 00876 說明 已發行股份（不包括庫存股份）數目 庫存股份數目 已發行股份總數 上月底結存 5,042,139,374 0 5,042,139,374 增加 / 減少 (-) 0 0 本月底結存 5,042,139,374 0 5,042,139,374 呈交日期: 2026年3月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00876 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 佳兆業健康集團控股有限公司 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 FF301 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 1. 股份分類 普通股 股份類別 不適用 於香港聯交所上市 (註1) 是 證券代號 (如上市) 00876 說明 已發行股份（不包括庫存股份）數目 庫存股份數目 已發行股份總數 上月底結存 5,042,139,374 0 5,042,139,374 增加 / 減少 (-) 0 0 本月底結存 5,042,139,374 0 5,042,139,374 足夠公眾持股量的確認(註4) | 根據《主板上市規則》第13.32D(1)條或第19A.28D(1)條 / 《GEM上市規則》第17.37D(1)條或第25.21D(1)條，我們在此確認，就上述所列股份類別而言，截至本月底: | | --- | | ✔ 已符合適用的公眾持股量要求（見下方） | | 未符合適用的公眾持股量要求（見下方） | ...

Core Viewpoint - As of January 15, a total of 105 stocks reached their 52-week highs, with notable performers including 德莱建业 (01546), 东曜药业－Ｂ (01875), and 大森控股 (01580) achieving high rates of 78.00%, 51.36%, and 37.61% respectively [1]. Summary by Category 52-Week Highs - 德莱建业 (01546) closed at 0.355, with a peak of 0.445, marking a high rate of 78.00% [1]. - 东曜药业－Ｂ (01875) closed at 4.190, reaching a high of 4.450, with a high rate of 51.36% [1]. - 大森控股 (01580) closed at 0.275, with a peak of 0.300, achieving a high rate of 37.61% [1]. - 顺兴集团控股 (01637) and 怡园酒业 (08146) also showed significant increases, with high rates of 36.36% and 24.74% respectively [1]. Additional Notable Stocks - JBB BUILDERS (01903) reached a high rate of 24.12% with a closing price of 2.830 [1]. - 天臣控股 (01201) and 江苏创新 (02116) had high rates of 15.38% and 15.00% respectively [1]. - 万国黄金集团 (03939) and 竣球控股 (01481) also performed well, with high rates of 12.95% and 12.44% respectively [1]. 52-Week Lows - The report also noted stocks reaching 52-week lows, with 天彩控股 (03882) showing a low rate of -14.42% [3]. - 中国智慧能源 (01004) and 基石控股 (01592) followed with low rates of -13.64% and -12.86% respectively [3]. - 弘毅文化集团－旧 (02990) and 中原建业 (09982) also reported significant declines of -9.09% and -6.06% respectively [3].

Group 1 - The company Kaisa Health (00876) announced a change in its auditor's name from "SFAI (HK) CPA Limited" to "ZSZH (HK) Fuson CPA Limited" [1] - The Chinese name of the auditor has also changed from "永拓富信会计师事务所有限公司" to "中审众环(香港)富信会计师事务所有限公司" [1] - This change will take effect from January 9, 2026 [1]

Group 1 - The company Kaisa Health (00876.HK) announced a change in its auditor's name from "SFAI(HK) CPA Limited" to "ZSZH(HK) Fuson CPA Limited" [1] - The Chinese name of the auditor has also changed from "永拓富信会计师事务所有限公司" to "中审众环(香港)富信会计师事务所有限公司" [1] - The changes will take effect from January 9, 2026 [1]

Group 1 - The company Kaisa Health (00876) announced a change in its auditor's English name from "SFAI(HK)CPA Limited" to "ZSZH(HK)Fuson CPA Limited" [1] - The Chinese name of the auditor has also changed from "永拓富信会计师事务所有限公司" to "中审众环(香港)富信会计师事务所有限公司" [1] - The changes will take effect from January 9, 2026 [1]

佳兆業健康集團控股有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司核 數師的英文名稱已由「SFAI (HK) CPA Limited」變更為「ZSZH (HK) Fuson CPA Limited」，而中文名稱已由「永拓富信會計師事務所有限公司」變更為「中審眾環（香 港）富信會計師事務所有限公司」，自二零二六年一月九日起生效。 Kaisa Health Group Holdings Limited 876 核數師更改名稱 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 承董事會命 佳兆業健康集團控股有限公司 主席兼執行董事 郭英成 香港，二零二六年一月十四日 於本公告日期，本公司執行董事為郭英成先生、羅軍先生、 羅婷婷女士、劉立好先生、謝斌鴻先生及葉豪達先生；及本公司獨立非執行董事 為劉彥文博士、呂愛平博士及李祉瑩女士。 ...